2023 World Conference on Lung Cancer (Posters)-P1.25. Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR

P1.25. Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR - PDF(Slides)

Back to course

Pdf Summary

The prevalence of EGFR mutations in patients with resected stage I-III non-small cell lung cancer (NSCLC) was studied in the Asian cohort of the EARLY-EGFR study. The study aimed to determine the prevalence of EGFR mutations, its subtypes, and treatment patterns in patients with early-stage NSCLC in Asian countries.<br /><br />The study enrolled 505 patients from 5 countries in Asia. The overall prevalence of EGFR mutations was 53.0%, with wide heterogeneity across Asia. The lowest rate was reported in India (26.0%), while the highest was in Singapore (63.8%). The prevalence of EGFR mutations in East Asian countries was 59.6%.<br /><br />The most common EGFR mutation subtypes found were exon-19 deletions (51.6%) and 21-L858R mutations (35.3%). The study also found that a higher proportion of EGFR mutations were found in stage I disease, females, and non-smokers.<br /><br />Only half of the patients with stage II-IIIB NSCLC were planned for adjuvant therapy, highlighting the need for more guideline-conform treatment. With the recent international guidelines recommending targeted therapy in early-stage NSCLC with actionable mutations, the study emphasizes the importance of upfront EGFR testing in routine clinical practice.<br /><br />Overall, the study provides real-world data on the prevalence of EGFR mutations in early-stage NSCLC in Asian countries and highlights the need for targeted therapies in these patients. The findings underscore the importance of implementing novel therapies and conducting upfront EGFR testing in routine clinical care for improved outcomes in patients with early-stage EGFR-mutated NSCLC.

Asset Subtitle

Tu Dao

Meta Tag

Speaker Tu Dao

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

EGFR mutations

non-small cell lung cancer

NSCLC

Asian cohort

prevalence

exon-19 deletions

21-L858R mutations

stage I disease

adjuvant therapy

targeted therapy